Methylene blue in place of acridine orange as a photosensitizer in photodynamic therapy of osteosarcoma.

Abstract

We recently established a unique therapeutic modality for musculoskeletal sarcomas, combining acridine orange (AO) with photodynamic surgery (PDS), photodynamic therapy (PDT) and radiodynamic therapy (RDT); excellent results were obtained in the inhibition of local tumor recurrence after intralesional excision. However, AO is not yet approved for clinical use and intravenous injection. Therefore, methylene blue (MB), which has a very similar chemical structure to AO and is already in clinical use for other diseases, was investigated. In vitro studies using mouse osteosarcoma (LM8) cells revealed that MB-PDT had a strong cytocidal effect and that MB was not radiosensitive, showing no effect in RDT. In vivo studies showed that MB did not specifically accumulate in mouse osteosarcoma tissue and that it did not inhibit tumor growth. MB is not a better photosensitizer than AO in PDS, PDT and RDT for osteosarcoma.

• Authors: Takao Matsubara, Katsuyuki Kusuzaki, Akihiko Matsumine, Haruhiko Satonaka, Ken Shintani, Tomoki Nakamura, Atsumasa Uchida
• Journal: In vivo (Athens, Greece) (In Vivo) 2008 May-Jun Vol. 22 Issue 3 Pg. 297-303 ISSN: 0258-851X [Print] Greece
• PMID: 18610739 (Publication Type: Journal Article)

Chemical References

• Photosensitizing Agents
• Acridine Orange
• Methylene Blue

Topics

• Acridine Orange (chemistry, therapeutic use)
• Animals
• Apoptosis (drug effects, radiation effects)
• Cell Line, Tumor
• Male
• Methylene Blue (chemistry, therapeutic use)
• Mice
• Mice, Inbred C3H
• Molecular Structure
• Osteosarcoma (drug therapy, pathology)
• Photochemotherapy
• Photosensitizing Agents (chemistry, therapeutic use)
• Survival Rate